Summary
AbbVie Inc. (ABBV) has filed an 8-K report on October 3, 2025, providing a preliminary update on its third-quarter 2025 financial results. The company anticipates a significant pre-tax charge of $2.7 billion related to acquired In-Process Research & Development (IPR&D) and milestones. This expense is expected to have an unfavorable impact of $1.50 per share on both GAAP and adjusted non-GAAP diluted earnings per share for the quarter. Investors should note that these results are preliminary and subject to finalization. This substantial IPR&D and milestone expense, which AbbVie does not typically forecast due to its unpredictable nature, will adjust the company's full-year 2025 adjusted diluted EPS guidance to a range of $10.38 - $10.58. The third-quarter 2025 adjusted diluted EPS guidance, including this charge, is now projected between $1.74 - $1.78. The company emphasizes that these are estimates and actual results may vary.
Key Highlights
- 1AbbVie anticipates a $2.7 billion pre-tax charge for acquired IPR&D and milestones in Q3 2025.
- 2This charge will negatively impact Q3 2025 GAAP and adjusted non-GAAP diluted EPS by an estimated $1.50 per share.
- 3Acquired IPR&D and milestone expenses are inherently unpredictable and not usually forecasted by AbbVie.
- 4Full-year 2025 adjusted diluted EPS guidance is revised to $10.38 - $10.58, incorporating the Q3 charge.
- 5Q3 2025 adjusted diluted EPS guidance is now projected to be between $1.74 - $1.78, including the impact of the expense.
- 6The reported Q3 results are preliminary and subject to final financial closing procedures.
- 7Exhibit 99.1 contains detailed guidance, including the estimated acquired IPR&D and milestones expense.